Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000556792 | SCV000630338 | uncertain significance | Biotinidase deficiency | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine with serine at codon 202 of the BTD protein (p.Asn202Ser). The asparagine residue is weakly conserved and there is a small physicochemical difference between asparagine and serine. This variant is present in population databases (rs397514376, ExAC 0.03%). This variant has not been reported in the literature in individuals affected with BTD-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000556792 | SCV002803847 | uncertain significance | Biotinidase deficiency | 2022-05-02 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000556792 | SCV002081556 | uncertain significance | Biotinidase deficiency | 2019-10-28 | no assertion criteria provided | clinical testing |